Fentanyl is a synthetic opioid that can be delivered through a transdermal therapeutic system (TTS). The aim of this study was to assess the efficacy of fentanyl TTS in treating oral mucositis pain in 75 adult hematopoietic stem cell transplant (HSCT) patients. The analysis was based on 62 patients who developed mucositis. Pain control was assessed by the patients using a visual analogue scale (VAS) from day 0 to day þ 33 after HSCT. Fentanyl TTS was administered at the patient's request. In all, 20 patients did not require fentanyl (group A). The first 22 patients asking for the patch received fentanyl 25 lg/h (group B) and the subsequent 20 patients received 50 lg/h (group C). There were no significant differences in pain relief between groups B and C. The expected effect of a decrease in mean pain score (mean of the VAS scores of all of the patients in the same group each day) following the application of fentanyl TTS was not noted. We can conclude that fentanyl TTS at the doses used in this study may not adequately relieve oral mucositis pain.
tation Oral mucositis is a major side effect of hematopoietic stem cell transplant (HSCT) with the resultant pain being a major source of morbidity. It may be reduced by routine mouthwashes with antiseptics, local steroids and local anesthetics, but most patients require opiate analgesics to control it.
1,2
Transdermal fentanyl is being increasingly used in the treatment of cancer pain. Fentanyl is a synthetic opioid with pure agonist activity and short-acting analgesic activity after intravenous or subcutaneous administration. Its low molecular weight, high potency (fentanyl is 75-100 times more potent than morphine on a molar basis) and high lipid solubility make it suitable for delivery by means of a transdermal therapeutic system (TTS), which is designed to release the drug into the skin at a constant rate between 25 and 100 mg/h, although multiple patches can be applied in order to achieve higher delivery rates. 3 Peak serum levels are reached within 8-12 h. The TTS delivers fentanyl continuously for 72 h and constant serum levels can be maintained by applying another patch. 4 It has been claimed that transcutaneous administration reduces opioid-induced side effects, such as constipation, nausea and vomiting, sedation, drowsiness and hypoventilation rates. 3, 5 The most common side effects are due to the adhesive used to attach the systems to the skin, and include erythema, itching and occasional pustule formation (o1%); their frequency is about 10% and they are generally mild. 5 Much of the early clinical experience with fentanyl TTS was obtained in patients with acute postoperative pain. However, because of the increased risk of respiratory complications, fentanyl TTS was contraindicated in this setting and is now recommended in chronic cancer pain, [6] [7] [8] and general pain including that of nonmalignant origin. 3, 9 The aim of this study was to evaluate the efficacy of fentanyl TTS in treating the pain related to oral mucositis in HSCT patients.
Patients and methods
This prospective study consecutively enrolled adult patients with hematological malignancies undergoing HSCT at the Bone Marrow Transplant Center, Ospedale Maggiore, Milan (Italy). All of the patients gave their written informed consent before entering the study. We did not ask for Ethics Committee approval because, like many other Cancer Centers, we already used fentanyl TTS for the treatment of pain and the study did not include a placebo group.
From the beginning of the conditioning therapy until hospital discharge, all of the patients received thrice-daily oral antimicrobial prophylaxis with nystatin oral suspension 100 000 U and a 0.2% chlorhexidine mouthwash 10 ml, and oral hygiene was performed three times a day using gauzes soaked in sodium bicarbonate solution under supervision of a nurse. All of the patients underwent a weekly oral examination by the same clinician who assessed the degree of oral mucositis using the scoring system proposed by the World Health Organization (WHO): 1 ¼ soreness, erythema; 2 ¼ erythema, ulcers, can eat solids; 3 ¼ confluent ulcers, requires liquid diet only; 4 ¼ oral alimentation not possible, hemorrhage. 10 Pain was measured by the patients once a day 12 am from the day of the transplant to day þ 33 using a visual analogue scale (VAS) 11 ranging from 0 (no pain) to 10 (worst pain), provided by the company producing fentanyl (Figure 1) . A mean pain score (MPS) was used to indicate the mean VAS scores of all of the patients each day. Fentanyl TTS was administered at the patients' request and a new patch of the same dose was applied every 72 h if necessary. Patients were informed about the nature of the drug releasing by the patch, but not about its dosage. The application site (upper torso) had to be free of any skin irritation.
No other topical or systemic agents were employed to reduce oral mucositis pain. Fentanyl side effects were recorded every day.
The aim of the study was to record systematically the effect of fentanyl TTS on mucositis pain in HSCT patients. Owing to the lack of published studies of oral mucositis and therefore data concerning the minimum effective dose, we initially used the patch with the lowest delivery rate (25 mg/h).
The study involved 75 hospitalized adult patients undergoing HSCT between November 2000 and December 2002. The 13 patients who did not experience oral mucositis were excluded from the analysis, which was therefore based on a total of 62 patients (82.7%: 34 males and 28 females) aged 19-67 years (average 47.9 years). Of the transplants, 17 were allografts (six from unrelated donors), nine were nonmyeloablative hematopoietic stem cell transplants (NHSCT) and 36 were peripheral blood stem cell (PBSC) autografts.
Of the 62 patients, 20 (32.2%) did not require fentanyl TTS (group A). The first 22 patients (35.6%) asking for the patch received fentanyl TTS 25 mg/h (group B). As our preliminary results 12 indicate that this dose was not sufficient to control mucositis-related pain in the majority of HSCT patients, the subsequent 20 patients (32.2%) received fentanyl TTS 50 mg/h (group C).
The demographic and transplantation details relating to the three groups are summarized in Tables 1 and 2 .
The The patients who did not ask for the patch (group A) had lower mucositis scores and a shorter duration of mucositis than those who asked for it (groups B þ C). These differences were highly significant (Wilcoxon's test: In order to analyze the efficacy of fentanyl TTS over time, the MPS (the mean VAS score of all of the patients in the same group on each day) was calculated in the three groups ( Figure 2 ). The three MPS curves are very similar in shape and timing. The shape of the curves seems to reflect the natural progression of mucositis-induced pain: the continuous increase during the first week due to worsening mucositis reached a plateau around day þ 8 and then gradually declined.
The expected effect of a decrease in MPS following the application of fentanyl TTS was not noted. The peak of curves B and C is much higher than that of curve A, indicating that the latter had a lower MPS every day. Paradoxically, the peak of curve C (fentanyl TTS 50 mg/h) is higher than that of curve B (fentanyl TTS 25 mg/h), despite the similarity of the two groups in terms of various parameters, including conditioning regimens, TBI and type of transplant. Group A consisted of patients who reported low pain scores and did not ask for fentanyl TTS; effective fentanyl TTS therapy should therefore have led to a change in the shape of curves B and C making them more similar to that of curve A. However, the shapes and distances of the three curves remained unchanged throughout the period of observation.
As almost immediate pain relief can be expected after the administration of opioid drugs, the efficacy of fentanyl TTS 25 and 50 mg/h was scored after 24 h of treatment. Figure 3a and b show that there was no significant difference between groups B and C (Fisher's exact test: p ¼ 0.75). In particular, 10/22 patients in group B (45.5%) and 6/20 in group C (30%) reported no change, 3/22 (13.6%) and 7/20 (35%) reported worsening pain and only 9/22 (40.9%) and 7/20 (35%) reported a response or a benefit 24 h after patch application.
Discussion
In our study, the incidence of mucositis was 83% and 68% of the patients requested the use of fentanyl TTS. The pain began an average of 4.2 days after transplantation, lasted 11.2 days and resolved by day þ 14.8. There were no differences in terms of pain duration, or the first or last day of pain, between the patients not requesting fentanyl TTS and those who were treated with fentanyl TTS 25 or 50 mg/ h. Furthermore, fentanyl TTS 50 mg/h was less effective than fentanyl TTS 25 mg/h in controlling the pain.
The published studies of the clinical efficacy of fentanyl TTS have largely been restricted to the setting of chronic pain and postsurgical patients. 3, 7 To the best of our knowledge, there is only one published report concerning the use of fentanyl TTS in the management of acute pain due to WHO grade 4 mucositis during high-dose chemotherapy and autologous HSCT, the results of which were positive. 13 The discrepancy between these and our findings may be due to differences in conditioning chemotherapy, the system used to measure pain and the fentanyl dose (they used 25, 50 and 75 mg/h, with sufficient analgesia being achieved mainly at the dose of 50 mg/h). The dose we used may well have been inadequate.
There are a number of problems related to the administration of fentanyl TTS to patients with pain due to oral mucositis. The pain varies during the day and depends, for example, on physical activity, distractions or the sight and smell of food and drink. 2 Patients vary widely in terms of symptom reporting, the duration of painful toxicities and their opioid pharmacokinetics and pharmacodynamics; furthermore, pain problems emerge not as unique symptoms but as prominent elements in the complex and evolving mosaics of bodily and emotional discomforts that vary widely across individuals.
14 Such variability of oral mucositis pain can represent a limitation to fentanyl TTS effectiveness, as such delivery system does not allow modification of the drug release in time, as happens, that is, with PCA (patient controlled analgesia). CTX=cytoxan; TBI=total body irradiation; CBV=CTX, BCNU, etoposide; BEAM=BCNU, etoposide, Ara-c, melphalan; ATG=thymoglobu-lin; RIC=reduced intensity conditioning. Table 3 Pain and mucositis scores in the three groups Several studies provide evidence that morphine is the opioid of first choice in the short-term management of pain associated with oral mucositis by means of PCA. We tried to use fentanyl TTS as an alternative treatment to morphine. We found no evidence that fentanyl TTS offers any clinical advantage in the short-term treatment of pain due to oral mucositis that follows HSCT. Of the patients, 18 (81.8%) in our group B and 18 (90%) in group C requested more than one patch during the hospitalization time. Given these high incidences of renewed demands, and assuming that patients suffering severe pain request the drug in order to obtain pain relief, it seems that neither of the studied regimens are effective in managing the pain caused by oral mucositis.
The nonrandomized design of the present study represents a limit of the validity of our results as does the limited dose used. The use of a subjective variable such as VAS scores to compare the efficacy of analgesic regimens with a pharmacological end point may be questionable. However, in the absence of a validated and objective means of measuring pain intensity, the judgment of patients is still the only way of assessing the effectiveness of a treatment. It was not an objective of our study investigating any relationship between severity of oral mucositis and pain. For this reason, although pain level was recorded every day, the WHO grade of mucositis was recorded only once a week.
The incidence of side effects associated with fentanyl TTS is very low, 5 but nausea and vomiting are difficult to assess in patients who have been exposed to antineoplastic drugs.
A study of a higher dose of fentanyl TTS may be warranted. The numbers on the y-axis indicate the difference in pain scores between the day on which the patch was applied (before the application) and the day after. Negative numbers: worsening pain; 0: no effect; positive numbers: pain relief.
